Skip to main content

Table 2 Overall response rates

From: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

  Patients (n) CR (%) PR (%) SD (%) PD (%)
Overall 31 1 (3.2) 9 (29) 12 (38.8) 9 (29)
2nd and 3rd line 11 0 (0) 5 (45.5) 6 (55.5) 0 (0)
4th and later line 20 1 (5) 4 (20) 6 (30) 9 (45)
FOLFIRI 19 1 (5.3) 6 (31.6) 8 (42.1) 4 (2.1)
FOLFOX 12 0 (0) 3 (25) 4 (33.3) 5 (41.7)
Same CT previously used      
   Yes 29 1 (3.5) 9 (31) 11 (37.9) 8 (27.6)
   No 2* 0 (0) 0 (0) 1 (50) 1 (50)
  1. CR; complete response, CT; chemotherapy; PR; partial response, SD; stable disease, PD; progression disease. * no previous treatment by FOLFOX in two patients treated by bevacizumab + FOLFOX